Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Devine T, Dai MS.

Curr Pharm Des. 2013;19(18):3248-62. Review.

2.

Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.

Di J, Zhang Y, Zheng J.

Curr Cancer Drug Targets. 2011 Oct;11(8):987-94. Review.

PMID:
21762075
3.

The significance of ubiquitin proteasome pathway in cancer development.

Yerlikaya A, Yöntem M.

Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):298-309. Review.

PMID:
23061719
4.

Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.

Allende-Vega N, Saville MK.

Semin Cancer Biol. 2010 Feb;20(1):29-39. doi: 10.1016/j.semcancer.2009.10.004. Epub 2009 Nov 6. Review.

PMID:
19897040
5.

Effects of MdmX on Mdm2-mediated downregulation of pRB.

Uchida C, Miwa S, Isobe T, Kitagawa K, Hattori T, Oda T, Yasuda H, Kitagawa M.

FEBS Lett. 2006 Mar 20;580(7):1753-8. Epub 2006 Feb 21.

6.

MDM2 promotes ubiquitination and degradation of MDMX.

Pan Y, Chen J.

Mol Cell Biol. 2003 Aug;23(15):5113-21.

7.

Dynamics in the p53-Mdm2 ubiquitination pathway.

Brooks CL, Gu W.

Cell Cycle. 2004 Jul;3(7):895-9. Epub 2004 Jul 2. Review.

PMID:
15254415
8.

Abnormal MDMX degradation in tumor cells due to ARF deficiency.

Li X, Gilkes D, Li B, Cheng Q, Pernazza D, Lawrence H, Lawrence N, Chen J.

Oncogene. 2012 Aug 9;31(32):3721-32. doi: 10.1038/onc.2011.534. Epub 2011 Nov 28.

9.
10.
11.

2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.

Xu J, Han M, Shen J, Guan Q, Bai Z, Lang B, Zhang H, Li Z, Zuo D, Zhang W, Wu Y.

Cancer Lett. 2016 Dec 1;383(1):9-17. doi: 10.1016/j.canlet.2016.09.011. Epub 2016 Sep 28.

PMID:
27693458
12.

The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.

Sparks A, Dayal S, Das J, Robertson P, Menendez S, Saville MK.

Oncogene. 2014 Sep 18;33(38):4685-96. doi: 10.1038/onc.2013.413. Epub 2013 Oct 14.

13.

Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.

Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW, Wahl GM.

Oncogene. 2012 Nov 8;31(45):4789-97. doi: 10.1038/onc.2011.625. Epub 2012 Jan 23.

14.

Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.

Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, Torres-Ramos M, Farrás R, Hay RT, Rodríguez MS.

Int J Biochem Cell Biol. 2010 May;42(5):725-35. doi: 10.1016/j.biocel.2010.01.010. Epub 2010 Jan 18.

PMID:
20080206
15.

Limiting the power of p53 through the ubiquitin proteasome pathway.

Pant V, Lozano G.

Genes Dev. 2014 Aug 15;28(16):1739-51. doi: 10.1101/gad.247452.114. Review.

16.

Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.

Qin L, Yang F, Zhou C, Chen Y, Zhang H, Su Z.

J Am Chem Soc. 2014 Dec 31;136(52):18023-33. doi: 10.1021/ja509223m. Epub 2014 Dec 17. Retraction in: J Am Chem Soc. 2015 Nov 18;137(45):14546.

PMID:
25453499
17.

[NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].

Shuvalov OY, Fedorova OA, Petukhov AV, Daks AA, Vasilieva EA, Grigorieva TA, Ivanov GS, Barlev NA.

Tsitologiia. 2015;57(12):847-54. Review. Russian.

PMID:
26995961
18.

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.

Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT.

Cell Cycle. 2008 Jun 1;7(11):1604-12. Epub 2008 Mar 17.

PMID:
18520179
19.

Mdm2 and MdmX partner to regulate p53.

Wang X, Jiang X.

FEBS Lett. 2012 May 21;586(10):1390-6. doi: 10.1016/j.febslet.2012.02.049. Epub 2012 Mar 8. Review.

20.

The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest.

Corcoran CA, Huang Y, Sheikh MS.

Cancer Biol Ther. 2004 Aug;3(8):721-5. Epub 2004 Aug 1.

PMID:
15280670

Supplemental Content

Support Center